Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fusidic acid sodium salt (SQ-16360) is a sodium salt form of fusidic acid, a bacteriostatic antibiotic derived from the fungus Fusidium coccineum and used as a topical medication to treat skin infections.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
100 mg | 在庫あり | ¥ 10,000 | |||
200 mg | 在庫あり | ¥ 14,000 | |||
500 mg | 在庫あり | ¥ 22,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 11,000 |
説明 | Fusidic acid sodium salt (SQ-16360) is a sodium salt form of fusidic acid, a bacteriostatic antibiotic derived from the fungus Fusidium coccineum and used as a topical medication to treat skin infections. |
In vivo | Fusidin(Fusidate Sodium) ameliorates EAM, at least partly, through an inhibitory action on the secretion of TNF-a[1]. It markedly attenuates clinical and histological signs of immunoinflammatory diabetes mellitus in mice given streptozotocin(SZ). The effect is dose-dependent, observed in three different strains of mice. Thus, fusidin might have an antidiabetogenic effect[2]. |
キナーゼ試験 | Binding assays: Binding assays are performed as previously described (Allenby et al., 1993, 1994). Briefly, labeled and unlabeled retinoids are added to nucleosol or cytosolic fractions in ethanol so that the total amount of ethanol added is constant in all tubes and did not exceed 2% of the incubation volume. The receptor preparations are incubated with retinoids at 4°C for 4–6 hr. Sephadex PD-10 desalting columns are used to separate bound radioligand from free radioligand after equilib- rium is achieved. For competitive binding assays, varying concentrations of unlabeled competing ligand are incubated with the appropriate nucleosol or cytosol in the presence of a fixed concentration of [3H]tRA (sp. act. 49.3 Ci/mmol) or [3H]9-cis RA (sp. act. 24.0 Ci/mmol). Final concentrations of [3H] tRA and [3H]9-cis RA for nuclear receptor binding assays are 5 nM. Final concentrations of [3H] tRA for CRABP binding assays is 30 nM. The IC50s are calculated as described above (DeLean et al., 1978). For saturation kinetics, increasing concentrations of radiolabeled ligand ([3H]tRA sp. act. 49.3 Ci/mmol, [3H]TTNPB sp. act. 5.5 Ci/ mmol) are added to the nucleosol of the appropriate receptor subtype in the presence (nonspecific binding) or absence (total binding) of a 100-fold molar excess of the corresponding unlabeled retinoid. Specific binding is defined as the total binding minus nonspecific binding. Saturation kinetics are calculated as previously described (Scatchard, 1949; Grippo and Gudas, 1987; Levin et al., 1992). |
別名 | Sodium fusidate, Fusidate Sodium, Fucidin, SQ-16360 |
分子量 | 538.69 |
分子式 | C31H47NaO6 |
CAS No. | 751-94-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 93 mg/mL (172.6 mM)
H2O: 92 mg/mL (170.8 mM)
DMSO: 93 mg/mL (172.6 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fusidic acid sodium salt 751-94-0 Microbiology/Virology Others oxidation-reduction CAT Antibiotic Antibacterial bacteriostatic Sodium fusidate ribosome Fusidic acid Bacterial factor Inhibitor SQ 16360 growth elongation inhibit steroids Fusidate Sodium Fucidin SQ16360 Fusidic acid sodium SQ-16360 inhibitor